RxDoctor Payments DataLook up a doctor →

Martha Arellano, MD

Hematology · Atlanta, GANPI 1952310500

Payments from drug & device makers

$1,208,386in general payments, 2019–2025

Across 193 payments — averaging $6261.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$288K
  • Syndax Pharmaceuticals, Inc.$224K
  • Sanofi US Services Inc.$172K
  • Servier Pharmaceuticals LLC$121K
  • AbbVie$107K
  • Macrogenics, Inc.$91K
  • plus $204K from 12 others
$682in research payments, 2019–2025

Across 3 payments — averaging $227.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Bioinnovation$574
  • Gilead$109

What the payments were for

  • Consulting fees$10,00083%
  • Speaking & faculty fees$5505%
  • Travel & lodging$1,0288%
  • Food & beverage$2822%
  • Education$2562%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208,386 in reported general payments places this provider in the 85th percentile of 27 hematology providers in Georgia.

See all hematology providers in Georgia

Medicare billing

Part B allowed, 2024
$30,914
Medicare patients
109
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib37$1,030,519
IclusigPonatinib Hcl19$426,863
TasignaNilotinib Hcl15$308,112
SprycelDasatinib27$307,070
BosulifBosutinib12$227,449
OnuregAzacitidine12$154,902
Imatinib Mesylate43$23,323
Tretinoin11$18,005
ValacyclovirValacyclovir Hcl46$1,260
Cyclosporine ModifiedCyclosporine, Modified11$889
Acyclovir17$821
Cefpodoxime Proxetil15$521
Hydroxyurea13$256
Allopurinol18$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Servier Pharmaceuticals LLCTibsovo$121,415$1,030,51937 claims
NovartisTasigna$615$308,11215 claims
PfizerBosulif$10,244$227,44912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 27 hematology providers in Georgia.

Other hematology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →